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ABSTRACT
Despite evidence about the implication of the bone marrow (BM) stromal 
microenvironment in multiple myeloma (MM) cell growth and survival, little is known 
about the effects of myelomatous cells on BM stromal cells. Mesenchymal stromal 
cells (MSCs) from healthy donors (dMSCs) or myeloma patients (pMSCs) were co-
cultured with the myeloma cell line MM.1S, and the transcriptomic profile of MSCs 
induced by this interaction was analyzed. Deregulated genes after co-culture common 
to both d/pMSCs revealed functional involvement in tumor microenvironment cross-
talk, myeloma growth induction and drug resistance, angiogenesis and signals for 
osteoclast activation and osteoblast inhibition. Additional genes induced by co-
culture were exclusively deregulated in pMSCs and predominantly associated to 
RNA processing, the ubiquitine-proteasome pathway, cell cycle regulation, cellular 
stress and non-canonical Wnt signaling. The upregulated expression of five genes 
after co-culture (CXCL1, CXCL5 and CXCL6 in d/pMSCs, and Neuregulin 3 and Norrie 
disease protein exclusively in pMSCs) was confirmed, and functional in vitro assays 
revealed putative roles in MM pathophysiology. The transcriptomic profile of pMSCs 
co-cultured with myeloma cells may better reflect that of MSCs in the BM of myeloma 
patients, and provides new molecular insights to the contribution of these cells to MM 
pathophysiology and to myeloma bone disease.
INTRODUCTION 
Multiple myeloma (MM) is a hematological 
malignancy characterized by the abnormal expansion of 
clonal plasma cells in the bone marrow (BM). It is widely 
admitted that the behavior of malignant plasma cells is 
not only dependent on their genomic abnormalities, 
but also, on the complex and reciprocal relationships 
of myeloma cells with their local BM niche [1, 2]. This 
BM microenvironment is a multifunctional complex 
network of extracellular matrix (ECM) proteins and 
non-hematopoietic cells, mainly of mesenchymal origin. 
Cross-talk of myeloma cells with this microenvironment 
is mediated by cell to cell, cell to ECM proteins or through 
soluble regulatory factors such as cytokines, chemokines 
and growth factors [3, 4]; protein, mRNA and miRNA 
interchange via MSC-derived exosomes has recently been 
reported as well [5]. These interactions have bidirectional 
consequences: on the one hand, myeloma cells perturb the 
BM homeostasis, causing anemia and immune suppression 
[6]. Further, these interactions may uncouple normal bone 
remodeling, reducing osteoblast (OB) differentiation and 
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function and promoting osteoclast (OC) formation and 
resorption, and leading to the development of osteolytic 
bone lesions [7, 8]. On the other hand, interactions of 
myeloma cells mostly with BM stromal cells and OCs, 
activate pleiotropic cascades of proliferative, survival 
and migration signaling pathways in myeloma cells, and 
protect them from chemotherapy-induced apoptosis [1, 9].
Mesenchymal stromal cells (MSCs) are the 
progenitors of most of the stromal components of the 
BM, capable of self-renewing and differentiation to 
OBs, chondrocytes, reticular fibroblasts, adipocytes and 
muscle cells [4, 10]. Several studies have compared MSCs 
derived from the BM of myeloma patients (pMSCs) and 
those from healthy donors (dMSCs) (reviewed in [11]). 
Although pMSCs showed a similar immunophenotype to 
that of dMSCs and supported long-term hematopoietic 
growth in like fashion [12, 13], they functionally and 
genetically differ from their healthy counterparts. 
Isolated and expanded pMSCs in culture showed non-
recurrent genomic alterations [14], displayed a deficient 
proliferative capacity and replicative potential [15] and 
produced abnormally high amounts of certain cytokines 
[12, 13, 16] compared to dMSCs. As well, pMSCs 
showed a premature senescence profile [17] and presented 
reduced efficiency to inhibit T-cell proliferation [18] 
and to differentiate into the osteoblastic lineage [13], as 
compared to dMSCs. In addition, gene expression profile 
(GEP) analyses revealed differential expression of genes 
in pMSCs coding for tumor-supportive and angiogenic 
factors, as well as for factors contributing to bone disease 
[13]. Even a distinct transcriptional pattern was found 
associated to the occurrence of bone lesions in pMSCs 
[19]. Since these differences have been found for isolated 
dMSCs and pMSCs after in vitro expansion, they are 
influenced by in vitro growth culture conditions and long-
term absence of myeloma interactions in pMSCs [13, 20]. 
Therefore these differences may only partially reflect true 
dissimilarities between pMSCs and dMSCs as occurring in 
the BM milieu of myeloma patients and healthy subjects. 
Although increasing number of studies are reporting on 
the expression of specific genes in myeloma-interacting 
MSCs [21-27], gene expression changes in co-cultured 
MSCs (with respect to mono-culture conditions) have not 
been done on a genome-wide basis.
Taking all this into consideration, in this work 
we have established co-cultures between BM derived 
MSCs and the MM.1S myeloma cell line, and performed 
GEP studies on the MSC population to determine those 
deregulated genes due to the co-culture condition with 
respect to MSCs in mono-culture. Both dMSCs and 
pMSCs have been used and compared. Our data provide 
new insights in the understanding of the intercellular 
communication signals between myeloma cells and 
MSCs, and further delineate the pivotal role of MSCs in 
the pathophysiology of MM and that of myeloma bone 
disease (MBD).
RESULTS
Experimental setting and expression profiling 
of d/pMSCs after co-culture with the MM.1S 
myeloma cell line
Four experimental conditions using transwell 
chambers were established as depicted in Fig. 1: (A) 
dMSCs in co-culture with MM.1S cells; (B) pMSCs in 
co-culture with MM.1S cells; (C) dMSCs cultured in the 
same manner but without MM.1S cells; and (D) pMSCs 
also cultured without MM.1S cells. Characteristics of 
MM patients and healthy donors are detailed in Supp. 
Table S1. After a 24 hour co-culture period, RNA was 
isolated from separated MSC populations and used to 
hybridize oligonucleotide microarrays. First, we identified 
differentially expressed genes when comparing d/pMSC 
samples in co-culture with d/pMSCs from the same origin 
in mono-culture. Next, in order to identify differentially 
expressed genes in d/pMSCs only due to the co-culture 
condition, intrinsic differences between dMSCs and 
pMSCs were excluded from the respective gene signatures 
in the co-cultured condition, both for dMSCs and pMSCs. 
Finally, by determining differentially deregulated genes 
common to both dMSCs and pMSCs after co-culture, 
we generated a deregulated “common list” of significant 
genes [FDR (false discovery rate) < 0.05] (List I in Fig. 
1), including 2583 genes, 699 upregulated and 1884 
downregulated from mono-culture (Supp. Table S2). The 
remaining differentially expressed genes observed in co-
cultured pMSCs but not present in the previous common 
list were considered exclusive of pMSCs. This “exclusive 
list” (List II in Fig.1) was set up with a FDR < 0.03, to 
allow a similar number of genes as in List I (2553 genes: 
1250 upregulated and 1303 downregulated with respect to 
the mono-culture condition; Supp. Table S3). 
Co-expression and cluster analyses of gene 
signatures obtained for d/pMSCs co-cultured with 
myelomatous cells
The expression heatmap from common deregulated 
genes in co-culture (List I) discriminated two main 
branches in the samples: one corresponding to the co-
culture condition, whereas the other corresponded to 
mono-cultured MSCs. Confirming the semi-supervised 
character of the analysis, MSCs from donor or patient 
origin did not segregate within each branch, since genes 
from intrinsic differences between dMSCs and pMSCs 
in mono-culture were excluded (Fig. 2A). Similarly, 
hierarchical clustering of data from deregulated genes in 
co-culture exclusive of pMSCs (List II), showed a clear 
segregation of samples from mono-culture and the co-
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Table 1. Functional signatures of upregulated genes due to co-culture with MM.1S and common to d/pMSCs (List I, 
FDR < 0.03). Specific functional categories were assigned by DAVID Bioinformatics Resources 6.7, GeneTerm Linker 
or manual curation, with values of statistical significance, silhouette width (when applicable), together with a list of the 
differentially and significatively expressed loci associated to each function. Genes marked with an asterisk (*) refer to 
genes not initially included in the functional enrichment analysis due to a FDR > 0.03, but subsequently incorporated 
because of their potential role in myeloma.
DAVID Bioinformatics Resources 6.7
Term Genes
Adjusted 
p-value 
(Benjamini)
Count 
/total 
list 
Population hits/total
Chemokine response (25 different genes)
Chemotaxis
CCL2, CCL20, CCL3, CCL4, CCL7, CMKLR1, 
CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCR4, DOCK2, FGF2, IL16, IL1B, IL6, IL8, 
ITGAM, PLAUR, PRKCA, RAC2, RNASE2, 
ROBO1
7,29E-06 24/464 160/13528
Chemokine 
activity
CCL2, CCL20, CCL3, CCL4, CCL7, CXCL1, 
CXCL2, CXCL3, CXCL5, CXCL6, IL8 1,79E-03 11/443 46/12983
Leukocyte 
migration 
chemotaxis
CCL2, CXCL3, DOCK2, IL16, IL1B, IL6, IL8, 
ITGAM, PRKCA, VCAM1 1,46E-02 10/482 57/14116
Immune / inflammatory response (45 different genes)
Inflammatory 
response
ATRN, C3, CCL2, CCL20, CCL3, CCL4, CCL7, 
CD44, CHST1, CR1, CXCL1, CXCL2, CXCL3, 
CXCL6, CXCR4, FN1, GPR68, IL1B, IL6, IL8, 
IRAK2, PDPN, S100A8, SERPINA1, SPP1, TLR8, 
VNN1
3,67E-03 27/482 325/14116
Positive 
regulation of T 
cell activation / 
proliferation
AP3B1, BLM, CD83, IL1B, IL6, PDCD1LG2, 
PTPRC, SOCS5, VCAM1, VNN1 1,08E-03 10/482 76/14116
Antigen 
processing and 
presentation 
of peptide or 
polysaccharide 
antigen via 
MHC class II
FCER1G, HLA-DPA1, HLA-DQA1, HLA-DQB1, 
HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-DRB5, 
IFI30
6,99E-03 8/482 33/14116
Angiogenesis (31 different genes)
Vasculature 
development 
/ blood vessel 
morphogenesis
ANGPT2, ANGPTL4, ANPEP, ARHGAP22, BGN, 
CD44, COL1A2, CXCR4, ECGF1, EREG, FGF2, 
GLMN, IL1B, IL8, ITGAV, MMP19, NRP1, PDPN, 
PTEN, PTK2, RASA1, ROBO1, TIPARP, VEGF
8,72E-03 25/482 211/14116
NA genes to angiogenesis function: ADAMTS6, HGF, MMP1, MMP3, MMP9, MMP12, MMP13, POSTN, SPP1
Proliferation and apoptosis (48 different genes)
Positive 
regulation of 
apoptosis
AHRR, BNIP3, BRCA1, CD44, CUL1, DYRK2, 
ETS1, GCH1, HIPK2, IL1B, KLF10, NR3C1, 
PDCD5, PLAGL1, PPP3R1, PREX1, PRKCA, 
PTEN, PTGS2, PTPRC, SMAD3, SOS1, TIAL1, 
TIAM1, TOP2A, TRIO, VDR
6,19E-02 29/464 430/13528
Regulation of 
mitosis
BIRC6, BUB1, C21ORF45, CCNK, CCNH, CDCA2, 
CDCA5, CDCA8, CDK2, ESPL1, HGF, HMGA2, 
KIF22, KIFC1, OIP5, SEPT2, TREX2, TXNL4B, 
UBE2C, ZWINT
4,90E-02 18/482 295/14116
Regulation 
of osteoclast 
differentiation
CA2, GNAS, KLF10 (2,22E-01)* 3/482 6/14116
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Extracellular matrix remodelation (31 different genes)
ECM-receptor 
interaction
CD44, COL1A2, COL4A2, COL6A3, FN1, IBSP, 
ITGA2, ITGAV, ITGB1, ITGB3, LAMC1, SPP1, 
TNC
1,08E-02 13/221 84/5085
Collagen COL1A2, COL4A2, COL6A3, COL7A1, COL12A1, COL16A1 8,47E-02 6/499 35/15908
Metal-thiolate 
cluster MT2A, MT1F, MT1G, MT1H, MT1M, MT1X, MT4 1,46E-04 6/210 12/19235
Collagen 
degradation MMP1, MMP3, MMP9, MMP13, MMP19 1,20E-02 5/460 25/19235
NA genes to ECM remodelation function: CTSS, MMP12, PLAUR
Bone biology (22 different genes)
Skeletal system 
development
ACP5, ANKH, CHST11, CMKLR1, COL12A1, 
COL1A2, DLX1, EXT1, GNAS, HOXB2, IBSP, 
KLF10, POSTN, PRKCA, PTGS2, SMAD3, SPP1, 
TIPARP, TNFRSF11A, VDR, NT5A
4,88E-02 23/482 319/14116
Gene Term Linker
Silhouette 
width Term Genes
Adjusted 
p-value 
(FDR)
Count / total list
Chemokine response related function (34 different genes)
0.606
Chemotaxis
Cytokine-cytokine 
receptor interaction
Chemokine 
signaling pathway
Chemokine activity
Small chemokine 
C-X-C /
Interleukin 8
NOD-like receptor 
signaling pathway
BIRC3, CCL2, CCL20, CCL3, CCL4, CCL7, 
CLCF1, CMKLR1, CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCR4, DOCK2, FGF2, 
GDF5, HGF, IFNGR2, IL16, IL1B, IL6, IL8, 
LIF, PDGFC, PLAUR, RAC2, RAF1, RNASE2, 
ROBO1, S100A8, SOS1, TNFRSF11A, 
TNFRSF21
3.98E-12 34/556
Cell interaction/communication related function (51 different genes)
0.270
External side of 
plasma membrane
Cell-matrix adhesion
Integrin-mediated 
signaling pathway
ADAMDEC1, ADAMTS1, ANPEP, APAF1, 
BGN, BIRC3, CD44, CD83, CDC42, CDK2, 
CHI3L1, COL12A1, COL16A1, COL1A2, 
COL4A2, COL6A3, COL7A1, CR1, CTSB, 
DDX26B, DST, FGF2, FN1, HGF, IBSP, ITGA2, 
ITGAM, ITGAV, ITGB, ITGB1BP1, ITGB3, 
LAMC1, PARVA, PDGFC, PIK3R5, PLEK, 
PRKCA, PTEN, PTGS2, PTK2, PTPRC, RAC2, 
RAF1, RAPH1, SOS1, SPP1, TFPI2, TIAM1, 
TNC, VCAM1, XRCC5
3.16E-19 51/556
Proliferation/apoptosis related function (37 different genes)
0.137
Regulation of 
apoptosis
Response to estradiol 
stimulus
APAF1, BIRC3, BRCA1, CAPN3, CCL2, 
CD44, CD82, CDCA8, CDK2, DAPP1, DUSP6, 
GADD45B, GCH1, GNAS, GRIA3, IL1B, 
ITGA2, LAMC1, PARVA, PDGFC, PIK3R5, 
POLS, PPP2R2A, PRKCA, PTEN, PTGS2, 
PTK2, PTPN12, PTPN2, PTPRC, PTPRE, RRM2, 
SERPINA1, SOD2, SRP54, TOP2A, TRIB1
1.30E-14 38/556
Other functions not annotated
Function Genes
MM plasma cell proliferation / 
drug resistance CCL2, CCL3, CD44, EXT1, FN1, HAS2, HGF, IL1B, IL6, IL8, IL16
Osteoclast formation and 
resorption CCL2, CCL3, CCL4, CCL20, CHSY1, IL1B, IL6, IL32, LIF
Inhibition of osteoblast 
differentiation and function CCL3, EREG
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Table 2: Functional signatures of upregulated genes due to co-culture with MM.1S and exclusive to pMSCs (List 
II, FDR < 0.02). Specific functional categories were assigned by DAVID Bioinformatics Resources 6.7, GeneTerm Linker 
or manual curation, with values of statistical significance, silhouette width (when applicable), together with a list of the 
differentially expressed loci associated with each function. Genes marked with an asterisk (*) refer to genes not initially 
included in the functional enrichment analysis due to a FDR > 0.02, but subsequently incorporated because of their potential 
role in myeloma.
DAVID Bioinformatics Resources 6.7
Term Genes
Adjusted 
p-value 
(Benjamini)
Count / 
total list 
Population 
hits/total
RNA processing (44 different genes)
RNA processing / 
RNA splicing
C1D, CCAR1, CPSF6, CSTF2, DHX9, DKC1, EXOSC8, 
FBL, FRG1, GRSF1, GTF2F2, KHDRBS1, NPM3, 
POLR2G, PPIH, PPIL1, PPP4R2, PTBP2, PUS1, QTRTD1, 
RBM17, RBM22, RBM3, RPL35A, RPP40, SF3B14, SF4, 
SFRS11, SFRS3, SLU7, SNRPB, SNRPB2, SNRPC, SR140, 
STRAP, SYNCRIP, TFB2M, U2AF1, UTP14A, WDR3, 
ZNF638
6,96E-07 42/371 547/14116
Ribonucleoprotein 
complex 
biogenesis
C1D, DKC1, EXOSC8, FBL, FRG1, GNL2, GTPBP4, 
NPM3, RPL35A, SLU7, SNRPB, SNRPC, TFB2M, 
UTP14A, WDR3
2,26E-02 15/371 180/14116
Proliferation (53 different genes)
Cell cycle regulation
AKAP8, APC, ATM, BTRC, CCAR1, CEP72, CETN3, 
CUL2, DMC1, DMTF1, DTYMK, E2F3, ESCO2, EVI5, 
KHDRBS1, KPNA2, LIG4, MAPK13, MCTS1, MDC1, 
MDM2, MDM4, MTBP, NEK4, NIPBL, PDCD6IP, PPP1CB, 
PPP1CC, PPP3CB, PSMB1, PSMC6, RANBP1, RBBP8, 
RPS27A, SH3BP4, SUGT1, UHMK1, USH1C
1,99E-03 42/371 776/14116
NA genes to proliferation function: BUB1B*, BUB3*, CCNA2*, CCNB2*, CCNC*, CCNF*, CCNT2*, CDC2*, CDC20*, 
CDC45L*, CDC5L*, CDC6*, CDCA1*, CDCA7L*, CDK7*, CDK8*, CENPE*, CENPF*, KNTC1*, MAD2L1*, ZW10*, 
ZWILCH* 
Ubiquitin proteasome pathway activation (35 different genes)
Cellular response 
to stress
APC, ATG10, ATM, CASP3, CIDEB, DCLRE1C, DHX9, 
ESCO2, EYA3, FGD4, HDAC2, HMGB1, JUN, LIG4, 
MCTS1, MDC1, PPP1CB, PRKDC, RBBP8, RBX1, RFC4, 
SLK, UBE2N, UBE2V2, WRN
3,16E-02 30/371 566/14116
Protein 
ubiquitination
CAND1, CBL, CBLL1, MDM2, MIB1, RBBP6, RPS27A, 
UBE2D2, UBE2N, UBE2V2, UBE3A 2,24E-02 12/371 119/14116
Gene Term Linker
Silhouette 
width Term Genes
Adjusted 
p-value 
(FDR)
Count 
/ total 
list
RNA processing (15 different genes)
0.612 Spliceosomal complexSpliceosome
CCDC12, FRG1, PPIH, PPIL1, RBM22, SF4, 
SFRS3, SLU7, SNRPB, SNRPB2, SNRPC, 
SR140, STRAP, SYNCRIP, U2AF1
2.97E-09 17/464
Ubiquitin proteasome pathway activation and oncogenic events (34 different genes)
0.232
Protein ubiquitination
Ubiquitin-protein ligase activity
Ubiquitin mediated proteolysis
Chronic myeloid leukemia
Ubiquitin-dependent protein 
catabolic process
Endocytosis
Prostate cancer
Cell cycle
ATM, BTRC, CAND1, CBL, CBLL1, CHMP5, 
CHUK, CREB3, CUL2, E2F3, HDAC2, MDM2, 
MIB1, PDCD6IP, PIAS2, PRKDC, PSMC6, 
RBBP6, RBX1, STAT5B, TCEB1, TCF7, 
TGFBR2, UBE2D2, UBE2J1, UBE2N, UBE2V2, 
UBE3A, USP13, USP24, USP4, VPS25, VPS37C, 
YWHAQ
9.05E-12 36/464
Wnt signaling pathway (11 different genes)
0.584 Wnt signaling pathway
APC, FBXW1, JUN, NFATC2, PPP3CB, 
PRICKLE2, RBX1, ROCK1, TCF7, WNT16, 
WNT7A
3.08E-05 11/464
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NA genes to Wnt signaling: NDP
Other functions not annotated
Function Genes
MM plasma cell proliferation / 
drug resistance ANXA1*, ANXA2P1, ANXA2P2, ANXA2P3, NRG3, WNT16
MSC immunomodulation PTGER2*, PTGES3*
MSC survival/pro-inflammation BIRC5*, HMMR*
Osteoblast inhibition HES1, CALD1, NFATc2
Various ABCC4*, NDP, WNT16
Figure 1: Experimental setting, microarray analysis workflow and subsequent analyses. Graphical representation of the 
four experimental conditions under consideration: (A) dMSCs in co-culture with MM.1S, (B) pMSCs in co-culture with MM.1S, (C) 
dMSCs in mono-culture, and (D) pMSCs in mono-culture, which were used to obtain pure MSC populations after the 24 h co-culture. 
Microarray comparisons were performed to identify deregulated genes in the co-culture condition for dMSCs and pMSCs after exclusion 
of genes already differentially expressed in dMSCs and pMSCs in mono-culture ([A vs C] - [D vs C] = cc.dMSC GEP, and [B vs D] – [D 
vs C] = cc.pMSC GEP]). Next, two lists of differentially expressed genes in MSCs after co-culture with MM.1S cells were generated and 
represented in the Venn diagrams: (i) List I: deregulated genes in co-culture common to dMSCs and pMSCs, and (ii) List II: deregulated 
genes in co-culture exclusive of pMSCs. Numbers shown indicate genes with are differentially up- or down-regulated with respect to the 
mono-culture condition in both lists. FDR cut-off value in List II was set up to 0.03 in order to obtain a number of differentially expressed 
genes equivalent to List I. Both lists of genes (I and II) were the starting point for subsequent bioinformatic analyses as well as functional 
assays for selected genes outlined below. 
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culture condition; however, we could not identify any 
further clusterization of pMSC samples relative to the 
occurrence of bone lesions, disease stage or other patient 
characteristics (Fig. 2B). 
Functional signatures linked to dMSCs and 
pMSCs co-cultured with MM.1S cells
By using DAVID (http://david.abcc.ncifcrf.
gov/) enrichment tool, the most statistically significant 
functional categories associated to common upregulated 
genes in co-culture were relative to chemokine response, 
immune-inflammatory response, angiogenesis, regulation 
of proliferation and apoptosis, extracellular matrix 
remodelation and bone biology (Table 1). Similar 
associated functions were identified for metagroups after 
use of GeneTerm Linker (http://gtlinker.dacya.ucm.es/): 
chemokine response, cell communication, cell-matrix 
adhesion and regulation of proliferation and apoptosis 
(Table 1). The functional signature on downregulated 
genes of List I had lower statistical significance and 
did not reveal different functions to those in Table I. 
Nevertheless, some downregulated genes from List I 
were manually curated because of a reported effect on OB 
differentiation and/or function (e.g. BMPR1A, CD276, 
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EFNB2, FZD4, HMOX1, IL6ST, BMP7, SMAD2).
In addition, differentially upregulated genes in 
co-culture exclusive to pMSCs, included genes linked 
with statistical significance to RNA processing and 
splicing, activation of the ubiquitine-proteasome pathway, 
regulation of cell cycle, cellular response to stress as well 
as to the Wnt signaling pathway (Table 2). Enrichment 
analysis was also performed on downregulated genes 
Figure 2: Hierarchical clustering of deregulated genes in MSCs due to co-culture with the MM.1S cell line. A, Hierarchical 
clustering of deregulated genes in co-culture, common to dMSCs and pMSCs (List I, FDR < 0.03). Rows represent individual genes (2583: 
699 upregulated and 1884 downregulated), whereas columns refer to each sample (a total of 37 MSC samples from donor or patient origin). 
The intensity of color saturation in each gene box (ranging from 2 to 14 in a log2 scale) depicts quantitative estimation of its expression 
level. Red color denotes high expression, increasing in brightness with higher values; green color denotes low expression, increasing 
brightness with lower values. White color denotes unchanged expression relative to the median expression value for each probeset. Samples 
are numerated in blue color for dMSCs and red color for pMSCs. B, Hierarchical clustering of deregulated genes in co-culture, exclusive of 
pMSCs (List II, FDR < 0.02). Rows represent individual genes (2553: 1250 upregulated and 1303 downregulated), whereas columns refer 
to each sample (a total of 21 pMSC samples, 9 in monoculture and 12 in co-culture). Color scale is the same as in A. 
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Figure 3: Expression of CXCL1, CXCL5 and CXCL6 by real-time PCR (A-C) and functional activities on myeloma 
cell proliferation (D), endothelial tube formation (E), migration of OC precursors (F) and MSC-MM cell adhesion 
(G). A-C, Expression levels for each gene were evaluated in dMSCs and pMSCs both in mono-culture or after 24 hour co-culture with 
the MM.1S cell line (n=7 for each type of MSC and culture condition), and normalized to GAPDH levels for each sample. Box plots 
represent fold-induction of gene expression in the co-culture condition relative to gene expression in mono-culture. D, MM.1S-luc cells 
were grown in 0.1% FBS containing medium in the presence or absence of specified concentrations of rh CXCL1, CXCL5 and CXCL6, 
and bioluminescence was measured after 3 days of culture. E, BMEC-1 cells were seeded on a Matrigel surface in medium containing 0.1% 
FBS and the specified chemokine concentrations for 5 hours. Tubule-like structures were counted under the microscope with the aid of a 
grid and micrographs are representative of maximal effects observed for each chemokine. F, Migration assays were performed by placing 
OC precursors in serum-limited conditions in the upper chamber and specified concentrations of rh CXCL1 diluted in the same medium in 
the lower chamber. Micrographs show representative CXCL1-mediated chemotaxis of OC precursors to the lower chamber after a 6 hour 
incubation time. G, MM.1S-luc cells were seeded on a monolayer of d/pMSCs in serum-free medium; after 3.5 hours, non-attached cells 
were removed by gentle PBS washes and bioluminescence signal measured. *p < 0.05.
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Figure 4: Expression of NRG3 and NDP (A, D) and functional activities of NRG3 (B, C) and NDP (E-G) in relation 
to myeloma pathophysiology. A, D, Expression of NRG3 and NDP in dMSCs and pMSCs co-cultured for 24 hours with the MM.1S 
cell line relative to that in mono-culture as assessed by real-time PCR and normalized to GAPDH levels for each sample (n=7 for each 
type of MSC and culture condition) *p < 0.05 **p < 0.01 between dMSCs and pMSCs. B, Secreted NRG3 from MM.1S and pMSC direct 
co-cultures was able to activate the ErbB4 receptor in the SK-N-BE neuroblastoma cell line. Conditioned media (CM) from MM.1S-
pMSC direct co-cultures was concentrated ~ 20 fold and added to overnight serum-deprived SK-N-BE cells in the presence or absence of 
neutralizing anti-NRG3 antibody. After 10 min, protein extracts were immunoprecipitated with the anti-ErbB4 antibody and immunoblotted 
with an antibody specific for p-Tyr. C, NRG3 shows activity as a myeloma growth factor augmenting the proliferation of the RPMI8226-luc 
myeloma cell line. The multiple myeloma cell line RPMI8226-luc was cultured in serum-limiting medium (0.1% FBS), half supplemented 
with concentrated CM from MM.1S-pMSC co-culture with or without neutralizing anti-NRG3 antibody as specified, and bioluminescence 
measured after 72 hours. E, Recombinant NDP dose-dependently promoted the growth of the RPMI8226-luc cell line grown in serum-
limiting conditions (0.1% FBS) for 72 hours. F, NDP induced the formation of tubule-like structures on the BMEC-1 cell line. BMEC-1 
cells were seeded on a Matrigel-coated surface in serum-limiting conditions in the presence of specific concentrations of recombinant NDP; 
after 5 hours, formation of tubule-like structures was assessed. G, PBMCs from healthy donors were cultured in osteoclastogenic medium 
for 21 days containing M-CSF only, M-CSF and RANKL, or M-CSF and different NDP concentrations; OC formation was quantified by 
TRAP+ staining of multinucleated (≥ 3 nuclei) cells. *p < 0.05. Representative micrographs are shown.
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Figure 5: Expression of CXCL1, CXCL5, CXCL6, WNT5A, IL8, MMP12 (from List I), and NDP, NRG3, ASPM, HMMR 
(from List II) by real-time PCR in d/pMSCs after co-culture with MM cells and leukemia cell lines. A, Co-cultures of 
pMSCs (n=3) and primary CD138+ myeloma cells (n=2) were established following the same experimental settings as those with the 
MM.1S cell line. Expression values for each sample were normalized to GAPDH levels, and the relative expression of the selected genes 
in pMSCs in the co-culture condition was referred to that in mono-culture arbitrarily set as 1. B, Co-cultures of dMSCs (n=3) and pMSCs 
(n = 3) with the RPMI-8226, OPM-2 and JJN3 myeloma cell lines were performed in the same manner as those previously established with 
the MM.1S cell line. After normalization to GAPDH levels, fold-induction in MSCs in the co-culture condition was represented relative to 
gene expression in mono-culture set as 1 (dashed line). C, In a similar manner, relative expression of the set of genes in MSCs was obtained 
after co-cultures of dMSCs (n=3) and pMSCs (n=3) with the HEL (erythroleukemia) and MEC-1 (chronic B lymphocytic leukemia) human 
cell lines. Bars in all graphs illustrate mean values ± SEM. 
Oncotarget8295www.impactjournals.com/oncotarget
Figure 6: Schematic representations for deregulated genes in MSCs after interaction with MM.1S cells. A, Predicted 
network when entering CXCL1, CXCL5 and CXCL6 genes from List I into the GeneMANIA and Cytoscape plugin allowing physical, 
signaling pathway and co-expression interactions. Node shape is hexagonal for the three query genes and circular for the rest of the 
predicted nodes of the network, whereas node color is proportional to its average fold change (FC) after co-culture with the MM.1S cell 
line (brighter red: higher FC after co-culture with respect to monoculture; white: absent in List I). Size of the nodes is indicative of its 
significance in the predicted network as determined by type and number of interactions. Physical interactions are depicted in blue, signaling 
pathway interactions in green and co-expression interactions in light gray; the strength of these interactions being indicated by line width. 
B, Schematic representation of Wnt canonical and non-canonical signaling, modified from www.Wikipathways.org. Upregulated genes on 
Lists I and II are shown in red, whereas downregulated genes on Lists I and II are coloured in green. 
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of List II, again not revealing additional functional 
annotations to the ones observed with upregulated genes. 
Diminished expression of certain genes in List II (such 
as CST3, FZD5, WNT3, C/EBPB, and GLI1) could be 
associated to inhibition of OB function due to their 
reported osteogenic roles. 
Manual curation was also used to reinforce coverage 
of bioinformatic tools and to add not annotated functions 
for genes with a reported role in myeloma pathogenesis 
(end of Tables 1 and 2).
Putative roles of CXCL1, CXCL5 and CXCL6 
chemokines in myeloma pathophysiology
The high level of expression and significance of 
three C-X-C motif chemokines (CXCL1/GROα, CXCL5/
ENA-78 and CXCL6/GCP-2) selected from List I was 
particularly interesting due to the known function of 
chemokines as regulators of multiple physiological and 
pathological processes. In agreement with our microarray 
data, CXCL1, CXCL5 and CXCL6 mRNA levels were 
shown to be highly upregulated in MSCs from both origins 
after co-culture (Fig. 3A-C).
The signaling receptor for CXCL1 and CXCL5 is 
CXCR2, while CXCL6 signals both through CXCR1 and 
CXCR2 [28]. Previous studies have demonstrated the 
presence of CXCR1 and CXCR2 receptors on MM cell 
lines and plasma cells from MM patients [29], suggesting 
that our selected chemokines may act as paracrine factors 
upon neoplastic plasma cells. We first tested the effect of 
recombinant human (rh) CXCL1, CXCL5 and CXCL6 
on proliferation of the multiple myeloma MM.1S-luc cell 
line. As shown in Fig. 3D, the three chemokines dose-
dependently and significantly increased the proliferation 
rate of MM.1S-luc cells by maximal effects of 39%, 54% 
and 35%, respectively. 
A well-stablished role for several members of the 
CXC chemokine family is the promotion of angiogenesis 
[30]. When we tested the putative angiogenic potential 
of the three chemokines, an increasing dose-response in 
the tubule formation assay was found for CXCL1 and 
CXCL5, even at lower concentrations than those required 
to induce myeloma growth (Fig. 3E). Since IL8 has been 
reported as an angiogenic factor in MM [31], is highly 
overexpressed by d/pMSCs after co-culture (Supp. Table 
S2) and also signals through CXCR1 and CXCR2 [28], we 
explored the possibility of CXCL1 and CXCL5 presenting 
a synergistic angiogenic effect with IL8. Combination of 
sub-maximal concentrations of CXCL1 and CXCL5 with 
IL8 seemed to render at least an additive effect in the 
endothelial tube formation assay (see Supp. Fig. S1). 
MBD is characterized by a double component of 
increased OC formation and resorption, whereas OB 
formation and function are impaired [7, 8]. Although we 
did not find any significative effect of CXCL1, CXCL5 or 
CXCL6 on the osteogenic or osteoclastogenic processes 
(data not shown), we observed that CXCL1 functioned 
as a chemoattractant for OC precursors (Fig. 3F), which 
express CXCR1 and CXCR2 receptors [32]. In the 
myeloma setting, this may favour their accumulation at 
sites of myeloma growth, where they could eventually 
differentiate to functional OCs. Finally, only CXCL6 
moderately, but significatively, increased the adhesion of 
the MM.1S cell line to either d/pMSCs (Fig. 3G).
Neuregulin-3
The expression and/or activation of the epidermal 
growth factor (EGF) family of tyrosine kinase receptors, 
such as ErbB receptors, has been shown to be implicated 
in normal plasma cell differentiation and in myeloma 
biology [33, 34]. Neuregulin-3 (NRG3), a member of 
the EGF family ligands, was selected from List II and 
its increased expression after co-culture only in pMSCs 
was validated by real-time PCR (Fig. 4A). To test the 
specific capacity of NRG3 to activate its unique ErbB4 
receptor and to function as a myeloma growth factor, we 
obtained the conditioned medium (CM) of MM.1S and 
pMSCs direct co-cultures. SK-N-BE neuroblastoma cells, 
which show high expression of the ErbB4 receptor, were 
exposed to this CM and NRG3-specific ErbB4 activation 
was observed after appropriate inmmunoprecipitation and 
immunoblotting procedures (Fig. 4B). This CM was also 
able to increase the growth rate of the RPMI8226-luc cell 
line, being its proliferating activity in great part dependent 
on NRG3 (Fig. 4C). 
Norrie Disease Protein
The Norrie disease protein (NDP) is a secreted 
protein recently identified as a non-conventional Wnt 
ligand capable of activating the canonical Wnt/β-catenin 
signaling pathway, via specific binding to frizzled receptor 
FZD4 and low density lipoprotein related LRP5/6 co-
receptor [35]. In accordance with our data in List II, real-
time PCR showed NDP to be highly overexpressed in co-
cultured pMSCs, whereas it was even repressed in dMSCs 
after co-culture (Fig. 4D). In this study, we show that rh 
NDP was able to promote the growth of the RPMI8226-
luc cell line (Fig. 4E) and to induce the formation of 
capillary tubes in the BMEC-1 cell line (see Fig. 4F) in a 
significative and dose-dependent manner. Moreover, NDP 
was able to induce osteoclastogenesis from peripheral 
blood mononuclear cells of healthy subjects in a dose-
dependent manner in the presence of M-CSF (macrophage 
colony-stimulating factor) and absence of RANKL 
(receptor activator of nuclear factor κ B ligand) (Fig. 4G). 
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Co-culture of bone marrow d/pMSCs with other 
myeloma cells and leukemia cell lines 
In order to get a cue of whether the observed GEPs 
in d/pMSCs after interaction with the MM.1S cell line 
were representative of transcriptional changes in MSCs 
in the myeloma context, co-cultures were performed with 
primary CD138+ myeloma cells and with other established 
MM cell lines (i. e. RPMI8226, OPM-2 and JJN3). The 
expression levels of the 5 selected genes in our study (i.e. 
CXCL1, CXCL5, CXCL6, NRG3 and NDP) together with 
the expression of 5 additional deregulated genes from our 
analyses [WNT5A, IL8, MMP12 (matrix metallopeptidase 
12) -from List I-; and ASPM (abnormal spindle homolog, 
microcephaly associated) and HMMR (hyaluronan-
mediated motility receptor) -from List II-], were evaluated 
by real-time PCR (Figs. 5A, B). As observed in Fig. 5A, 
an upregulated expression of the 10 genes under study 
was observed in pMSCs when they were co-cultured with 
CD138+ myeloma cells, with even higher fold changes 
in co-culture than with the MM.1S cell line. A more 
heterogeneous response was observed, however, in d/
pMSCs co-cultured with the RPMI8226, OPM-2 or the 
JJN3 cell lines (Fig. 5B). Although increased expression 
levels were evident for most of the genes under study, fold 
changes varied relative to co-culture with the MM.1S cell 
line. Also, the “pMSC exclusive” condition of genes from 
List II (NDP, NRG3, ASPM and HMMR) was lost in co-
cultures with these other MM cell lines, since increased 
expression was observed on both dMSCs and pMSCs. 
To test whether the gene expression changes in 
BM MSCs also occurred after interaction with other 
types of tumor cells, the relative expression levels of 
our set of genes was evaluated in d/pMSCs after co-
culture with HEL (erythroleukemia) and MEC-1 (chronic 
B lymphocytic leukemia) human cell lines (Fig. 5C). 
These two cell lines were selected as representatives of 
acute myeloid leukemia (AML) and chronic lymphocytic 
leukemia (CLL) tumor cells, since similarly to MM, these 
two hematologic malignancies course with accumulation 
of tumor cells in the BM microenvironment. Of interest, 
an exacerbated expression of some of the evaluated genes 
(i. e. CXCL1, CXCL5, CXCL6, IL8) and strong expression 
of others (i. e. NDP, NRG3, MMP12) was observed in 
d/pMSCs after co-culture with the leukemic cell lines, 
which is suggestive of a specific role for these molecules 
in the biology of these hematological tumors. Other genes 
from List II (i. e. ASPM and HMMR) did not greatly vary 
their expression in co-culture with HEL or MEC-1cell 
lines with respect to mono-culture conditions, perhaps 
insinuating a more exclusive role of these molecules in 
MM pathophysiology. 
Transcription factor profile analysis
The analysis of putative transcription factor binding 
sites (TFBS) in the promoter regions of our deregulated 
genes in MSCs after co-culture (Lists I and II), allowed to 
infer the main TFs which might be regulating the observed 
changes in gene expression after co-culture with the 
MM.1S cell line (Supp. Table S4A). TFs with the highest 
number of TFBS and gene hits were Elk1 [36] and Gfi1 
[37] in List I; and Elk4 [36] and GABPA [38] in List II. 
Interestingly, in the myeloma context, Gfi1 has recently 
been pointed out as a new transcriptional repressor of 
Runx2, blocking OB differentiation and being increased 
both in MSCs from MM patients and MM-bearing mice 
[24]. Among the multiple target genes regulated by these 
four transcription factors, many have been reported to be 
critical for MM pathogenesis (Supp. Table S4B).
DISCUSSION
During the last two decades, the importance of 
the tumor microenvironment for the acquisition of 
cancer capabilities by neoplasic cells and thus for cancer 
progression, has become increasingly clear [39, 40]. In the 
case of MM, the well-organized cellular and functional 
architecture of the BM is converted into a “privileged” 
tumor microenvironment greatly supporting the growth, 
progression, survival and drug resistance of myelomatous 
cells [3]. Therefore, the design of better and more 
effective anti-myeloma treatments partly relies on a better 
understanding of the reciprocal interactions of myeloma 
and tumor microenvironment cells in the BM. Being MSCs 
a relevant component of the tumor microenvironment in 
MM, in this study we have specifically focused on the 
“not so much studied” gene expression changes in MSCs 
induced by interaction with myeloma cells; these changes 
in MSCs further contribute to myeloma growth, survival 
and progression and compromise normal MSC function 
(e. g. contributing to the reduced pMSC osteogenic 
potential). It should be noted that the ability to induce gene 
expression changes in BM derived-MSCs is not exclusive 
of myeloma tumor cells. In fact, specific gene expression 
changes were observed for a subset of 10 selected genes 
from our study when d/pMSCs were co-cultured with 
acute myeloid and chronic lymphocytic leukemica cell 
lines (see Fig. 5C). Our piece of data not only gives 
further evidence of the important role of the BM stromal 
microenvironment in these hematological malignancies 
[41-44], but also opens the door for future research based 
on genome-wide expression studies in BM stromal cells 
interacting with leukemia cells. 
In our study, we specifically illustrate a 
comprehensive transcriptomic analysis of BM-derived 
MSCs (from healthy donors and MM patients) after 
establishment of both cellular and molecular interactions 
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with the MM.1S myeloma plasma cell line. We believe 
that the GEP of MSCs after interaction with the MM.1S 
cell line may be representative of gene expression changes 
as occurring in pMSCs in the BM of myeloma patients. 
In fact, a similar relative expression for the commented 
10 selected genes from our analyses was observed in 
pMSCs after co-culture with either the MM.1S cell line or 
primary myeloma cells (Fig. 5A). However, it should also 
be acknowledged that some differences in gene expression 
changes for the same subset of genes were observed in d/
pMSCs co-cultured with different MM cell lines (Fig. 5B). 
This may be indicative of qualitative and/or time-course 
differences in gene expression changes induced in MSCs 
when interacting with different types of myeloma cells. 
Apart from a better understanding of the complex 
interactions between myeloma cells and MSCs, our 
analyses intended to identify deregulated pathways in 
MSCs due to these interactions which may influence the 
progression, therapeutic resistance, dissemination of MM 
and/or development of MBD. We also aimed to gain some 
insight into the evolution of the disease by determining 
which myeloma-induced transcripts were common 
to dMSCs and pMSCs and which were deregulated 
exclusively in pMSCs.
Deregulated genes after co-culture common to 
dMSCs and pMSCs (List I)
The differentially upregulated genes in List I were 
functionally linked to: i) a chemokine/cytokine response, 
since these molecules have effectively been implicated in 
several aspects of MM biology (myeloma cell proliferation 
and survival, homing and/or drug resistance, angiogenesis, 
OC precursor recruitment and bone destruction) [1, 2, 28]; 
ii) an immune and inflammatory response, which could 
be related to the reported diminished immunomodulatory 
potential of pMSCs [18]; iii) angiogenesis (e. g. 
ANGPTL4, FGF2) [13, 31]; iv) microenvironment cross-
talk, including cell-matrix adhesion (e. g. COL12A1, 
ITGB1) or integrin-mediated and extracellular matrix 
remodelation (e. g. ITGA2, ITGAM, VCAM1, MMP1, 
MMP3, MMP9, MMP12) [3, 45, 46]; and v) bone biology 
and skeletal development [(e. g. SPP1 (osteopontin) 
[47]]. Manual curation based on the literature, further 
revealed functions of these deregulated genes related to 
myeloma growth and drug resistance (e. g. IL6, CCL3, 
HGF, FN1) [3, 20, 48], OC formation and/or activation 
(e. g. CCL3, CCL20, LIF) [26, 48, 49] and inhibition 
of OB differentiation and function (e. g. CCL3, EREG) 
[50, 51]. Other molecules identified as promoters of 
OB differentiation and/or function in myeloma (e. g. 
EFNB2, HMOX1) [52, 53] and in other contexts (e. g. 
CD276, BMP7, IL6ST) [54-56], showed a downregulated 
expression after co-culture (Supp. Table S2).
As observed in our functional in vitro assays, 
the three selected highly upregulated chemokines 
in co-cultured d/pMSCs (i. e. CXCL1, CXCL5 and 
CXCL6) supported important roles in myeloma growth, 
angiogenesis, recruitment of OC precursors and myeloma-
cell adhesion. In fact, serum levels of CXCL1 and 
CXCL5 chemokines have been found to be significantly 
elevated in MM patients, and in the case of CXCL1, to 
increase with disease stage [57]. Serum concentrations of 
CXCL1 and CXCL5 in myeloma patients were below the 
concentrations used in our in vitro studies (186.5 ± 129.1 
pg/ml and 765 572.1 pg/ml, respectively [57]). However, 
higher physiological concentrations of these cytokines are 
expected to be found in the BM at sites of MSC-myeloma 
cell interactions, which would support their angiogenic 
and myeloma growth activities. When we entered these 
three genes as a query in the GeneMANIA-Cytoscape 
tool, an association network of 22 genes was represented 
(Fig. 6A). Importantly, 16/22 of the nodules appearing 
in the network were included in List I. Some of the 
nodules not present in List I (e. g. CXCR1, CXCR2 and 
DARC) corresponded to common receptors for the three 
cytokines, suggesting a paracrine activity of the secreted 
CXCL chemokines on myeloma cells or other cells in 
the BM microenvironment. Represented interactions of 
these chemokines and matrix metalloproteinases (MMP9, 
MMP1 and MMP3) may be related to ECM remodeling 
associated to chemokine activity; alternatively, these 
interactions may respond to posttranslational cleavage of 
the chemokines to modify their biological potency [58]. 
Other nodules in the network correspond to cytokines 
with known function in myeloma pathophysiology and/
or in osteolytic lesions (IL6, IL1β, CCL2, IL8 and 
CCL20) [8, 28, 59]. Specifically, IL8, being one of the 
most highly overexpressed genes in co-cultured d/pMSCs 
in our study, has been found to be elevated in serum of 
MM patients [31]. IL8 expression in myeloma has been 
related not only to increased angiogenesis [31], but 
also to proliferation and chemotaxis of myeloma cells 
[60] and stimulation of osteoclastogenesis and bone 
resorption [61]. Another upregulated gene in co-cultured 
MSCs and shown in the network is that corresponding to 
the non-canonical Wnt ligand Wnt5A. Wnt5a has been 
identified by GEP analyses as a myeloma growth factor 
expressed in myeloma cells and OCs from myeloma 
patients [20]. Although Wnt5a has been reported to 
promote osteoblastogenesis of human MSCs through Fzd 
receptors and Ror2 [62], it has been found that myeloma 
cells in co-culture with pre-OBs inhibit Ror2 expression 
in the latter, thus impairing osteogenic differentiation 
and contributing to OB suppression [63]. Interestingly, 
increased osteoclastogenesis has been found to be 
mediated by signaling between Wnt5a (secreted by OB-
lineage cells) and the membrane receptor Ror2 (expressed 
in OC precursors) [64], which suggests that the Wnt5a-
Ror2 axis may contribute to increased OC formation and 
bone resorption in MBD.
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Deregulated genes after co-culture exclusive to 
pMSCs (List II)
Two of the major functions associated to deregulated 
genes in List II were RNA processing and activation of 
the ubiquitin-proteasome pathway (UPP). These functions 
probably reflect the response of pMSCs to cope with 
the high transcriptional and protein secretory load after 
myeloma cell interaction. Upregulated expression of genes 
implicated in mRNA maturation and disposal of misfolded 
proteins would likely be necessary for pMSCs to maintain 
an adequate cellular function. Interestingly, upregulated 
expression of transcripts from the UPP were also found 
in the transcriptional signature of myeloma cells in the 
presence of stromal cells [65]. 
Wnt signaling is a critical pathway for OB 
differentiation and bone metabolism [66, 67] which is also 
deregulated in pMSCs after co-culture. Commitment of 
MSCs to osteogenic differentiation and to promotion of 
bone formation has majorly been associated to activation 
of the Wnt canonical pathway [66, 68]; however, 
mounting evidence is arising for non-canonical Wnt 
signaling also regulating OB differentiation and function 
[69-72]. Altogether, our analyses seem to point out an 
inhibition of the canonical Wnt signaling in co-cultured 
pMSCs (see Fig. 6B), both because of upregulated 
expression of several non-canonical Wnt ligands (WNT5A, 
WNT5B -from List I-, WNT7A and WNT16 -from List 
II-), and because of upregulated expression of negative 
regulators of β-catenin (APC, RBX1 and FBXW1) which 
would promote β-catenin ubiquitination for proteasome 
degradation [73]. Besides, the upregulated expression of 
some members of the non-canonical Wnt/Ca2+ and Planar 
Cell Polarity pathways (e. g. CDC42 and ROCK1), may 
perhaps indicate a possible enhancement of the migration 
and invasiveness properties of co-cultured pMSCs as some 
authors have described in other cell types [74].
Both d/pMSCs after co-culture show a deregulated 
expression of genes involved in proliferation and 
apoptosis. More specifically, pMSCs after interaction with 
MM.1S cells also present upregulated expression of genes 
implicated in cell cycle regulation (including numerous 
mitotic spindle components as well as interphase and 
mitosis checkpoints; see Tables 1 and 2, and Supp. 
Tables S2 and S3 [75]). Besides, deregulated genes in 
co-cultured pMSCs present functional association with 
cellular response to stress (including genes transduction 
to oxidative-stress stimuli, endoplasmic reticulum stress 
and DNA damage response; Table 2). Taken together, 
interactions with myeloma cells seem to greatly influence 
the proliferative potential of MSCs, which may be related 
to the reduced growth rate of pMSCs and/or the premature 
onset of senescence observed in pMSCs when grown 
in vitro as compared to dMSCs [15, 17]. Further gene 
expression and functional studies on MSCs with longer 
co-culture times are warranted to shed light onto these 
issues. 
Other genes exclusively upregulated in pMSCs and 
not directly included in the commented functions (Table 
2, “Other functions not annotated”), might be implicated 
in several aspects of myeloma pathophysiology, such 
as myeloma cell adhesion and growth (e. g. ANXA2P1, 
ANXA2P2 [23]), or inhibition of OB differentiation (e. 
g. GFI1 [24]). The downregulated expression of several 
genes in pMSCs after co-culture (e. g. CST3 [76], FZD5 
[72], WNT3 [77], C/EBPB [78], and GLI1 [79]; see Supp. 
Table S3) may also contribute to the reported impairment 
of OB function in MM.
The putative role of the upregulated expression of 
NRG3 and NDP from List II was also explored. NRG3 
and its receptor have been found to be expressed in 
myeloma cells but not in their normal counterparts [34]. 
Besides, NRG3 has been reported to be significantly 
overexpressed by myeloma cells as compared to other 
cells in the BM microenvironment [20]. In this study, we 
show that pMSCs co-cultured with myeloma cells also 
secrete NRG3, which is able of activating ErbB4 and 
to promote myeloma proliferation, thereby creating a 
paracrine amplification loop for myeloma growth. On the 
other hand, our experiments showed that rh NDP increased 
the growth of a MM cell line and induced the formation of 
capillary tubes, being the latter capability in line with the 
reported function of NDP in the control of formation of 
retinal capillaries [35]. Interestingly, we also showed that 
NDP increased OC formation in the presence of M-CSF 
and absence of RANKL. Since as far as we know NDP has 
not been related to myeloma, our data suggest a putative 
role for this factor in the pathophysiology of the disease 
and in the development of ostelytic lesions.
Some authors have proposed the idea of a co-
evolution of MSCs and myeloma cells along the course 
of the disease [3, 11]. In this sense, dMSCs would 
progressively convert to pMSCs, being the interactions 
with myelomatous cells determinant for those changes. 
Consistent with this hypothesis, common deregulated 
genes in MSCs after 24 hours of co-culture with MM.1S 
cells may daringly be considered as gene expression 
changes occurring in MSCs at initial phases of myeloma 
(i. e. production of myeloma growth and angiogenic 
factors, chemokines, chemoattraction of OC precursors, 
OC activation and OB inhibition). Following the same 
line of reasoning, genes deregulated after co-culture 
exclusively found in pMSCs, may perhaps be considered 
as expression changes predominantly affecting proper 
MSCs at latter stages of myeloma disease (i. e. changes 
in MSCs to cope with enhanced protein secretion, cellular 
response to stress, and regulation of Wnt signaling).
In summary, we have shown that the transcriptomic 
profile of pMSCs co-cultured with myeloma cells greatly 
differs from that of MSCs in mono-culture, may better 
reflect the expression signature of MSCs in the BM 
of myeloma patients, and provides new insights to the 
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contribution of interacting MSCs to the pathophysiology 
of MM and MBD. Our data also bring up the issue that due 
to interactions with myeloma cells, MSCs are modified 
from a dMSC phenotype to one bearing the prototypic 
characteristics of pMSCs. Further, our studies support that 
therapeutic targeting of myeloma-stromal cell interactions 
would benefit from both an anti-myeloma effect and from 
maintenance of appropriate MSC function. 
METHODS
Samples and Ethical statements
BM samples from 12 healthy donors and 19 newly 
diagnosed MM patients were obtained after written 
informed consent of participants, and used for MSC 
isolation and expansion (d/pMSCs) or for isolation of 
CD138+ primary plasma cells. 
Research was conducted in accordance to ethical 
standards and principles expressed in the Declaration of 
Helsinki. The study was approved by the Institutional 
Review Board from the Centro de Investigación del 
Cáncer, IBMCC (University of Salamanca-CSIC, Spain). 
Reagents and immunochemicals
Recombinant human (rh) CXCL1, CXCL5, CXCL6, 
M-CSF and RANKL were purchased from PeproTech and 
rh NDP from R&D Systems. Primary antibodies were 
produced in-house (ErbB4) or purchased from Santa Cruz 
Biotechnology (p-Tyr, NRG3). Trypan Blue solution 0.4% 
was delivered by Sigma-Aldrich, cell culture media and 
supplements by Gibco (Life Technologies), and epidermal 
growth factor (EGF) and Matrigel from BD Biosciences. 
Cells and culture conditions
Cell lines
The human MM cell line MM.1S was provided 
by Dr ST Rosen (Northwestern University, Chicago, IL, 
USA), whereas the MM.1S-luc cell line was donated 
by Dr CS Mitsiades (Dana-Farber Cancer Institute, 
Boston, MA, USA). RPMI8226 cells purchased from 
the American Type Culture Collection (ATCC) were 
lentivirally transduced to stably express firefly luciferase 
as in Groen et al. [80]. Other established MM cell lines 
(OPM-2, JJN3), together with the erythroleukemia 
(HEL) and chronic B lymphocytic leukemia (MEC-
1) cell lines were purchased from the Leibniz Institute 
DSMZ biosource center. All hematological tumor 
cell lines were periodically authentified by STR DNA 
profiling, and grown in RPMI 1640 medium or IMDM 
(MEC-1) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL 
streptomycin and 2 mM L-glutamine. 
The BM endothelial cell line BMEC-1 was provided 
by Dr FJ Candal (Centers for Disease Control and 
Prevention, Atlanta, Georgia, USA). This cell line was 
grown in MCDB 131 medium containing 15% FBS, 2.5 
µg/ml amphotericin B, 1 µg/ml hydrocortisone, 10 ng/
ml EGF and antibiotics. The human neuroblastoma cell 
line SK-N-BE was purchased from ATCC and grown in 
DMEM medium (4.5 g/l glucose) with 10% FBS and 
antibiotics. 
Primary mesenchymal stromal cells, osteoblasts, 
macrophages and osteoclasts
Primary MSCs from BM samples of healthy 
donors (n=11) and MM patients (n=17) were isolated 
and expanded as described by Garayoa et al. [14]. At 
passage 2, d/pMSCs were used in co-culture experiments 
with the MM.1S cell line and subsequently subjected to 
GEP analyses (clinical characteristics of patients used are 
shown in Supp. Table S1). In addition, some d/pMSCs 
were co-cultured with leukemia cell lines or primary MM 
cells, or utilized in OB differentiation experiments. 
Methods for in vitro OB (n=4) and OC (n=4) 
differentiation have been previously reported [81]. Briefly, 
OC precursors were generated from PBMCs of healthy 
donors in α-MEM with 10% FBS and antibiotics and 
supplemented with 25 ng/ml M-CSF for 4 days; OBs were 
differentiated from primary MSCs by culture in osteogenic 
medium containing β-glycerol phosphate, ascorbic acid 
and dexamethasone. 
Primary CD138+ plasma cells
Two BM samples from untreated myeloma patients 
at diagnosis were used to isolate primary myeloma cells 
via CD138-positive selection using the AutoMACs 
separation system (Miltenyi-Biotec) with a final purity 
> 95%. These primary myeloma cells were subsequently 
used in co-culture studies with pMSCs. 
Co-culture system
Co-cultures were performed using a 6-well format 
transwell system with 1 µm pore size membrane (BD 
Biosciences). Briefly, 1.2 x 105 MSCs (passage 2) were 
first cultured attached to the lower side of the membrane, 
and when a confluency of ≅ 85% was reached, 1 x 106 
MM.1S cells were seeded on the upper side (see Supp 
Methods, co-culture system). After a 24 hour co-culture 
in RPMI 1640 medium supplemented with 10% FBS and 
antibiotics, d/pMSCs were recovered by trypsinization and 
processed for total RNA extraction (Qiagen). 
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RNA isolation, cDNA synthesis and microarray 
hybridization
After assessment of RNA integrity (Agilent 2100 
Bioanalyzer, Agilent), biotinylated complementary RNA 
was synthesized (Enzo) and hybridized to HG-U133 
Plus 2.0 GeneChip oligonucleotide arrays (Affymetrix). 
Quantitation of fluorescence intensities of probesets was 
done using the GeneArray Scanner (Hewlett Packard). 
Microarray data have been deposited at GEO database 
(ref GSE46053).
Microarray data analysis: normalization, signal 
calculation, differential gene expression and 
clustering
The RMA (robust multi-array average) algorithm 
was applied for background correction, intra- and 
inter-microarray normalization and expression 
signal calculation. The SAM (significance analysis 
of microarrays) algorithm was used to identify gene 
probesets displaying significant differential expression 
when comparing d/pMSCs after co-culture with MSCs 
from the same origin in mono-culture, using p-value cut-
offs determined by the FDR method. The corresponding 
matrix of expression values was analyzed with the 
hierarchical cluster analysis using algorithm hclust. All 
these methods were applied using R (http://www.r-project.
org) and Bioconductor (http://www.bioconductor.org).
Gene functional enrichment analysis 
Functional enrichment analysis was performed on 
selected sets of genes after differential expression analyses 
using two bioinformatics tools: DAVID Bioinformatics 
Resources 6.7 (http://david.abcc.ncifcrf.gov/) [82] and 
GeneTerm Linker (http://gtlinker.dacya.ucm.es/) [83]. The 
gene sets analyzed for functional enrichment were the most 
significant from List I (upregulated genes with FDR<0.03) 
and List II (upregulated genes with FDR<0.02). The 
downregulated significant genes were also analyzed in 
separated runs. For construction and analysis of gene 
functional networks we used the GeneMANIA resource 
(http://www.genemania.org/) and Cytoscape (http://www.
cytoscape.org/). 
Transcription factor profile analysis
Prediction of transcriptional regulators for the 
differentially expressed genes was obtained using 
TransFind and oPOSSUM tools (http://transfind.sys-bio.
net/; http://burgundy.cmmt.ubc.ca/oPOSSUM/), which 
look for enrichment in consensus transcription factor 
binding sites (TFBS) in promoters of specific gene sets 
using JASPAR and TRANSFAC databases.
Real-time PCR analysis
TaqMan Gene Expression Assays (Applied 
Biosystems, Foster City, CA, USA) were used according 
to manufacturer’s instructions. Assay IDs were: CXCL1, 
Hs00236937_m1; CXCL5, Hs00171085_m1; CXCL6, 
Hs00237017_m1; NRG3, Hs01377907_m1; NDP, 
Hs00181129_m1; WNT5A, Hs00998537_m1; IL8, 
Hs00174103_m1; MMP-12, Hs 00899662_m1; ASPM, Hs 
00411505_m1; HMMR, Hs00234864_m1. Experiments 
were performed as previously described [81].
Proliferation assay
MM.1S-luc cells were seeded in 96-well plates (1 x 
104 cells/well) in RPMI 1640 medium with 0.1% FBS and 
specified concentrations of each recombinant protein. After 
72 hours, firefly luciferine was added and bioluminescence 
measured in a Xenogen IVIS 50 Bioluminiscent System 
(Caliper Life Sciences). 
Migration assay
We used a 24-well plate with transwells having 
5.0 µm pore size membranes (Corning). Serial dilutions 
of recombinant proteins in α-MEM with 0.5% FBS were 
placed in the lower chamber, whereas macrophages (2 x 
105 cells/100 µl) were added to the upper chamber. After 
3 hours, cells that had migrated and adhered to the bottom 
of the lower chamber were stained with haematoxylin and 
counted with Trypan Blue solution.
Tube formation assay
BMEC-1 cells (5 x 103 cells/well) were seeded onto 
Matrigel-coated 96-well plates in MCDB 131 medium 
supplemented with 0.1% FBS and indicated doses of the 
recombinant proteins. After 5 hours, tubule-like structures 
were counted using a 1 mm2 grid, and photographed in an 
Axiovert 135 (Zeiss) microscope. 
Adhesion assay 
Both d/pMSCs (1 x 104 cells/well) were incubated 
in 96-well plates for 24 hours and then MM.1S-luc cells 
(1 x 105 cells/well) were added to the monolayer in serum-
free medium with specified doses of recombinant proteins. 
After 3.5 hour incubation, unbound MM.1S-luc cells were 
removed with three gentle PBS washes and adhered cells 
quantified by bioluminescence.
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Mineralization and OC formation assays
To evaluate the effect of the recombinant proteins on 
OB/OC differentiation and function, matrix mineralization 
and osteoclastogenesis were quantitatively evaluated as 
previously described [81].
Statistical analyses
Each condition was analyzed in triplicate or 
quadruplicate and data were presented as the mean ± SD or 
SEM (as specified) of at least 3 independent experiments. 
Statistical comparisons were performed using the Mann-
Whitney U test and considered significant for p<0.05 
(SPSS Statistics 15.0).
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